Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. I
Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. II
Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole
Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes
Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics. III
Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man
Role of CYP3A enzymes in the biotransformation of triazolam in rat liver
Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4
Disposition and pharmacokinetics of temozolomide in rat